Covista/$CVSA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Covista
Covista Inc is America's healthcare educator across five accredited institutions: Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. It delivers education to its students at multiple campuses and online. Its segments are Chamberlain, Walden, and Medical and Veterinary. Walden generates maximum revenue and includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. The Company generates maximum revenue from Domestic operations.
- Ticker
- $CVSA
- Sector
- Consumer Discretionary
- Primary listing
- NYSE
- Employees
- 4,754
- Headquarters
- Chicago, United States
- Website
- www.covista.com
Covista Metrics
BasicAdvanced
$4.3B
17.99
$7.05
0.62
-
Price and volume
Market cap
$4.3B
Beta
0.62
52-week high
$156.26
52-week low
$86.97
Average daily volume
333K
Financial strength
Current ratio
1.093
Quick ratio
0.965
Long term debt to equity
0.599
Total debt to equity
0.626
Interest coverage (TTM)
8.58%
Profitability
EBITDA (TTM)
444.775
Gross margin (TTM)
57.34%
Net profit margin (TTM)
12.87%
Operating margin (TTM)
19.94%
Effective tax rate (TTM)
22.53%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.45%
Return on equity (TTM)
18.57%
Valuation
Price to earnings (TTM)
17.985
Price to revenue (TTM)
2.273
Price to book
2.98
Price to tangible book (TTM)
-16.02
Price to free cash flow (TTM)
11.311
Free cash flow yield (TTM)
8.84%
Free cash flow per share (TTM)
11.206
Growth
Revenue change (TTM)
9.27%
Earnings per share change (TTM)
13.95%
3-year revenue growth (CAGR)
10.44%
10-year revenue growth (CAGR)
6.11%
3-year earnings per share growth (CAGR)
51.02%
10-year earnings per share growth (CAGR)
63.26%
What the Analysts think about Covista
Analyst ratings (Buy, Hold, Sell) for Covista stock.
Analyst projections of the future price of Covista stock.
Bulls say / Bears say
Covista beat its raised fiscal 2026 targets, with revenue up 9.3% and adjusted EPS up 23.7%. It expects further growth in fiscal 2027, with revenue guidance of $2.05bn–$2.09bn. (Covista)
Walden offers a strong growth engine: enrolment rose 14% in the fourth quarter to a record high, extending its run of year-on-year growth to 12 quarters. Continued growth there could support group results. (Covista)
Campus expansion and health-system partnerships give Covista ways to reach more nursing students and employers. Chamberlain plans to open campuses in Cincinnati and Salt Lake City in fiscal 2027, alongside newly announced collaborations with major health systems. (Covista)
Covista’s 10-K warns that regulatory action or loss of Title IV eligibility at one institution could threaten aid eligibility across its other institutions. That creates a regulatory risk capable of affecting the whole group, not just one school. (Stock Titan)
Management said some Medical and Veterinary students brought enrolment forward ahead of federal Grad PLUS loan changes. If that timing shift leaves fewer students for later intakes, near-term enrolment comparisons could be weaker. (Benzinga)
The fiscal 2027 outlook implies slower growth: Covista guides to 5–7% revenue growth and 8–11% adjusted EPS growth, versus 9.3% and 23.7%, respectively, in fiscal 2026. That raises the risk that recent earnings momentum will cool. (Covista)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
Covista Financial Performance
Revenues and expenses
Covista Earnings Performance
Company profitability
Upcoming events
No upcoming events
Covista News
AllArticlesVideos
Funds containing Covista
AllUSDEURGBP
Fund name | Fund size | $CVSA weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.25% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.25% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.15% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.15% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.